Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Posted:
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study.
Reed Jobs is keen for his $1bn venture capital fund Yosemite to make a difference.
The 34-year-old runs an oncology-focused venture capital fund that manages more than $1bn in assets, and is in the UK looking for investment opportunities.
Read…
SMA is a rare, inherited condition that causes progressive muscle weakness, affecting movement, breathing and swallowing. People living with spinal muscular atrophy (SMA) in England are set to gain routine access to two potentially life-changing treatments, following our publication of final…
Attendees
Sponsors and Exhibitors
Contact us